New Effective Targets
Sunil Verma, MD, MSEd, FRCPC
Video Categories: ESMO 2016
Sunil Verma, MD, MSEd, FRCPC discusses new classes of therapies for HR+ Breast Cancer.
Dixie-Lee Esseltine, MD and George Mulligan, PhD offer insight on the impact of ixazomib on Takeda Oncology’s approach to multiple myeloma care and its approach to other cancer types.
Alexander Bastian speaks about the need for a sustainable model of pricing as related to cancer treatments and drug development. He talks about indication-based pricing or tumor-based pricing—says that is compelling, but not necessarily possible in the US.